

TRANSMITTAL FORM

Application Number 10/823,932 Filing Date April 13, 2004 First Named Inventor Nielsen, Loretta Art Unit 1614 Examiner Name Lacourciere, K. Attorney Docket Number

(to be used for all correspondence after initial filing) 016930-003713US Total Number of Pages in This Submission

		ENCLOSURES (Che	ck all that apply	<i>'</i>)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Pape Petition Petition to Convert to a Provisional Application Power of Attorney, Rev. Change of Corresponded Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table	ocation ence Address e on CD	Aft Ap of / Ap (Ap (Ap	peal Cor Appeals peal Cor opeal Noti oprietary atus Lett her Encle low): stcard 8A & PT ce Copie	osure(s) (please identify
	SIGNA	 TURE OF APPLICANT, A	TTORNEY (OR AGEN	т	
Firm Name	Townsend and Town			, AGEN	•	
Signature	Mask	a Ceell				
Printed name	Nathan S. Cassell		(3.)			
Date	February <u></u> , 2005		Reg. No.	42,396		
	CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Signature		~ ~				
Typed or printed r	name Tiffany Wu				Date	February <u></u>

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 016930-003713US

Commissioner for Patents
P. Box 1450
Alcandria, VA 22313-1450

TOWNSEND and TOWNSEND and CREW LLP

Tiffany Wu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen et al.

Application No.: 10/823,932

Filed: April 13, 2004

For: COMBINED TUMOR

SUPPRESSOR GENE THERAPY AND

CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS

Examiner: Lacourciere, K.

Art Unit: 1614

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Nielsen et al. PATENT

Application No.: 10/823,932

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Mother Carl

Nathan S. Cassell Reg. No. 42,396

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

NSC:ewm 60414196 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(400 40 404 404 404 404 404 404 404 404						
Sheet	1	of	2				

	Complete if Known
Application Number	10/823,932
Filing Date	April 13, 2004
First Named Inventor	Nielsen, Loretta
Art Unit	1614
Examiner Name	Lacourciere, K.
Attorney Docket Number	016930-003713US

	U.S. PATENT DOCUMENTS+						
		Document Number					
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	ļ						
			 				
	 						
	ļ						
			ļ	<u> </u>			
-			<u> </u>				
	ļ						

				FOREIGN PA	TENT DOCUM	ENIS		
		Foreign Patent Document				Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.¹	Country Code ³	Number⁴	Kind Code ^s (<i>If known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T
	1	wo	98/28948	A1	11-02-1995	Board of Regents, The University of Texas		
								ΙC
								T
		1						
					<u> </u>			П

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional).
Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.
Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.
Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/823,932			
Filing Date	April 13, 2004			
First Named Inventor	Nielsen, Loretta			
Art Unit	1614			
Examiner Name	Lacourciere, K.			
Attorney Docket Number	016930-003713US			

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
	2	Tishler et al., Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53, Cancer Res. 1995 Dec 15;55(24):6021-5.			
			_		
			$oxed{oxed}$		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.